Welcome to our dedicated page for Gain Therapeutics news (Ticker: GANX), a resource for investors and traders seeking the latest updates and insights on Gain Therapeutics stock.
Gain Therapeutics, Inc. (Nasdaq: GANX) is a clinical-stage biotechnology company whose news flow is closely tied to the development of its lead drug candidate, GT-02287, and to progress in its broader allosteric small molecule pipeline. The company focuses on next generation allosteric therapies targeting neurodegenerative diseases, rare genetic disorders and oncology, with a primary emphasis on Parkinson’s disease.
News about Gain Therapeutics frequently covers clinical milestones for GT-02287, including updates from its Phase 1 and Phase 1b studies in people with Parkinson’s disease with or without a GBA1 mutation. Press releases have detailed safety and tolerability findings, exploratory biomarker data such as reductions in glucosylsphingosine (GluSph) in cerebrospinal fluid, and observations related to Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) scores. These items provide insight into how the company interprets GT-02287’s potential disease-modifying effects and mechanism of action.
Investors and observers can also expect regular announcements on preclinical research and scientific presentations. Gain Therapeutics reports data from preclinical models that explore GCase modulation, mitochondrial and lysosomal health, and neuroprotection in Parkinson’s disease. Poster presentations at scientific meetings, such as Neuroscience conferences and Parkinson’s-focused congresses, are common subjects of the company’s news releases.
Additional news items include corporate updates and financial disclosures, such as quarterly financial results, capital raises, changes in board composition, and shareholder meeting outcomes. The company also issues notices about participation in investor conferences, key opinion leader (KOL) events, and webinars that discuss biomarkers, clinical endpoints and emerging data from GT-02287 studies.
For readers following GANX, the news page provides a centralized view of clinical trial progress, scientific data, regulatory and corporate developments, and event participation related to Gain Therapeutics’ efforts in allosteric small molecule drug development.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Gain Therapeutics, Inc. (Nasdaq: GANX) announced the appointment of C. Evan Ballantyne as Chief Financial Officer, effective immediately, succeeding Salvatore Calabrese. Ballantyne brings over 20 years of experience in healthcare finance, having previously served as CFO at OncXerna Therapeutics and Orchestra Biomed. He has a track record of raising significant capital, including $30 million at OncXerna and $57 million at Orchestra. Under his guidance, Gain Therapeutics aims to transition to a clinical-stage company with its lead program targeting GBA1 Parkinson's disease entering the clinic this year. The company has also granted Ballantyne equity awards as an inducement for joining. Gain Therapeutics focuses on allosteric small molecule therapies with a pipeline targeting neurodegenerative diseases and metabolic disorders.
Gain Therapeutics, Inc. (GANX) announced promising pre-clinical data supporting the potential therapeutic effects of its allosteric small molecule therapies for Alzheimer’s disease. Presented at the 2023 AD/PD Conference, the data shows that their compounds significantly improve neuronal survival and reduce toxicity from Amyloid Beta and Tau proteins in cell models. The STAR compounds exhibit disease-modifying properties, showcasing their potential to avert neurodegeneration associated with Alzheimer’s disease. Gain Therapeutics aims to advance research in allosteric regulators, with further updates expected throughout the year.